vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $422.8M, roughly 1.7× EDGEWELL PERSONAL CARE Co). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -15.5%, a 34.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs -11.6%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-137.5M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs -16.0%).
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
EPC vs MEDP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $708.5M |
| Net Profit | $-65.7M | $135.1M |
| Gross Margin | 38.1% | — |
| Operating Margin | -4.5% | 21.6% |
| Net Margin | -15.5% | 19.1% |
| Revenue YoY | -11.6% | 32.0% |
| Net Profit YoY | -3028.6% | 15.5% |
| EPS (diluted) | $-1.41 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $422.8M | $708.5M | ||
| Q3 25 | $600.5M | $659.9M | ||
| Q2 25 | $627.2M | $603.3M | ||
| Q1 25 | $580.7M | $558.6M | ||
| Q4 24 | $415.1M | $536.6M | ||
| Q3 24 | $517.6M | $533.3M | ||
| Q2 24 | $647.8M | $528.1M | ||
| Q1 24 | $599.4M | $511.0M |
| Q4 25 | $-65.7M | $135.1M | ||
| Q3 25 | $-30.6M | $111.1M | ||
| Q2 25 | $29.1M | $90.3M | ||
| Q1 25 | $29.0M | $114.6M | ||
| Q4 24 | $-2.1M | $117.0M | ||
| Q3 24 | $8.8M | $96.4M | ||
| Q2 24 | $49.0M | $88.4M | ||
| Q1 24 | $36.0M | $102.6M |
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 42.8% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | — | ||
| Q2 24 | 44.3% | — | ||
| Q1 24 | 43.1% | — |
| Q4 25 | -4.5% | 21.6% | ||
| Q3 25 | -4.2% | 21.5% | ||
| Q2 25 | 8.6% | 20.9% | ||
| Q1 25 | 10.1% | 20.3% | ||
| Q4 24 | 2.2% | 23.4% | ||
| Q3 24 | 3.9% | 21.1% | ||
| Q2 24 | 12.8% | 19.9% | ||
| Q1 24 | 11.7% | 20.4% |
| Q4 25 | -15.5% | 19.1% | ||
| Q3 25 | -5.1% | 16.8% | ||
| Q2 25 | 4.6% | 15.0% | ||
| Q1 25 | 5.0% | 20.5% | ||
| Q4 24 | -0.5% | 21.8% | ||
| Q3 24 | 1.7% | 18.1% | ||
| Q2 24 | 7.6% | 16.7% | ||
| Q1 24 | 6.0% | 20.1% |
| Q4 25 | $-1.41 | $4.65 | ||
| Q3 25 | $-0.65 | $3.86 | ||
| Q2 25 | $0.62 | $3.10 | ||
| Q1 25 | $0.60 | $3.67 | ||
| Q4 24 | $-0.04 | $3.67 | ||
| Q3 24 | $0.18 | $3.01 | ||
| Q2 24 | $0.98 | $2.75 | ||
| Q1 24 | $0.72 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $1.5B | $459.1M |
| Total Assets | $3.8B | $2.0B |
| Debt / EquityLower = less leverage | 1.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | — | $669.4M | ||
| Q3 24 | $209.1M | $656.9M | ||
| Q2 24 | — | $510.9M | ||
| Q1 24 | — | $407.0M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $1.5B | $459.1M | ||
| Q3 25 | $1.6B | $293.6M | ||
| Q2 25 | $1.6B | $172.4M | ||
| Q1 25 | $1.5B | $593.6M | ||
| Q4 24 | $1.5B | $825.5M | ||
| Q3 24 | $1.6B | $881.4M | ||
| Q2 24 | $1.6B | $763.6M | ||
| Q1 24 | $1.6B | $671.5M |
| Q4 25 | $3.8B | $2.0B | ||
| Q3 25 | $3.8B | $1.8B | ||
| Q2 25 | $3.8B | $1.6B | ||
| Q1 25 | $3.8B | $1.9B | ||
| Q4 24 | $3.7B | $2.1B | ||
| Q3 24 | $3.7B | $2.1B | ||
| Q2 24 | $3.7B | $1.9B | ||
| Q1 24 | $3.8B | $1.8B |
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.89× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.95× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | $192.7M |
| Free Cash FlowOCF − Capex | $-137.5M | $188.1M |
| FCF MarginFCF / Revenue | -32.5% | 26.6% |
| Capex IntensityCapex / Revenue | 2.7% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-125.9M | $192.7M | ||
| Q3 25 | $74.1M | $246.2M | ||
| Q2 25 | $114.8M | $148.5M | ||
| Q1 25 | $45.1M | $125.8M | ||
| Q4 24 | $-115.6M | $190.7M | ||
| Q3 24 | $-388.3M | $149.1M | ||
| Q2 24 | $101.2M | $116.4M | ||
| Q1 24 | $129.0M | $152.7M |
| Q4 25 | $-137.5M | $188.1M | ||
| Q3 25 | $46.5M | $235.5M | ||
| Q2 25 | $99.3M | $142.4M | ||
| Q1 25 | $28.0M | $115.8M | ||
| Q4 24 | $-132.4M | $183.0M | ||
| Q3 24 | $-414.2M | $138.5M | ||
| Q2 24 | $88.6M | $103.5M | ||
| Q1 24 | $117.5M | $147.2M |
| Q4 25 | -32.5% | 26.6% | ||
| Q3 25 | 7.7% | 35.7% | ||
| Q2 25 | 15.8% | 23.6% | ||
| Q1 25 | 4.8% | 20.7% | ||
| Q4 24 | -31.9% | 34.1% | ||
| Q3 24 | -80.0% | 26.0% | ||
| Q2 24 | 13.7% | 19.6% | ||
| Q1 24 | 19.6% | 28.8% |
| Q4 25 | 2.7% | 0.6% | ||
| Q3 25 | 4.6% | 1.6% | ||
| Q2 25 | 2.5% | 1.0% | ||
| Q1 25 | 2.9% | 1.8% | ||
| Q4 24 | 4.0% | 1.4% | ||
| Q3 24 | 5.0% | 2.0% | ||
| Q2 24 | 1.9% | 2.4% | ||
| Q1 24 | 1.9% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | 3.95× | 1.65× | ||
| Q1 25 | 1.56× | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | -44.13× | 1.55× | ||
| Q2 24 | 2.07× | 1.32× | ||
| Q1 24 | 3.58× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
